media centre
Iva Nikolic promoted to Chief Technology Officer
22 September

This week we’re celebrating the achievements of Iva Nikolic, PhD, our newly appointed Chief Technology Officer!

Formerly our Director of Functional Genomics and Screening, Iva’s unparalleled expertise in the highthroughput analysis of gene function has made her a core member of the oNKo Innate team. Iva’s creativity and vision continue to enable our discovery platform to stand apart from traditional approaches and answer some of the toughest questions in immuno-oncology. Beyond her technical prowess, Iva’s expertise in cancer biology shapes our understanding of the targets identified in our discovery research and helps develop these into viable pipeline programs.

Her enthusiasm, decision-making, and leadership skills allow her to navigate technical issues with finesse and make tough calls when they’re needed. She also ensures our different teams work as a cohesive unit, tackling cancer from all angles with our integrated technologies.

As our Chief Technology Officer, Iva will drive the development and implementation of new technologies at oNKo, enabling discoveries that will form the basis for a new wave of therapeutics. Congratulations Iva, and thank you for your unwavering enthusiasm and leadership – we couldn’t do it without you!

Iva will be at the Discovery on Target conference next week in Boston – if you’re attending, check out her presentation on our discovery platform

media centre
All media
All media
Iva Nikolic promoted to Chief Technology Officer
oNKo-innate named Australian Emerging Company of the Year 2021
The cancer–natural killer cell immunity cycle
Monash University and oNKo-innate Announce Research Partnership
Onko-Innate, Gilead, Kite Work On NK Cancer Immunotherapies
Immunotherapy biotech scores Gilead partnership
Interest builds in next-generation cancer immunotherapies
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies
Gilead, Kite pen natural killer pact with little-known Australian cell therapy player
Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
Announcing research collaboration with Gilead and Kite
You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients
Quantifying NK cell growth and survival changes in response to cytokines and regulatory checkpoint blockade helps identify optimal culture and expansion conditions
Congratulations to our CSO for winning the 2019 Jacques Miller Medal
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Molecular insight into targeting the NK cell immune response to cancer
The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
IL-15 signaling in NK cell cancer immunotherapy
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
Targeting natural killer cells in cancer immunotherapy
CIS is a potent checkpoint in NK cell-mediated tumor immunity
A crucial role for the homeodomain transcription factor Hhex in lymphopoiesis
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo